The UK’s Cell and Gene Catapult (CGT Catapult) completed six additional production modules in a bid for the UK to remain competitive in the booming cell and gene therapy drug development business. The first six clean room at capacity due to high demand at the...
Lisa Urquhart reports that with the growing gene therapy development pipeline comes the need for manufacturing capacity. Will biopharma firms buy or build? Buy will often be the answer when feasible. The $1.2 billion all cash deal represents a considerable premium....
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok